The mission of Speechify is to make sure that reading is never a barrier to learning. Over 50 million people use Speechify’s text-to-speech products to turn whatever they’re reading – PDFs, books, Google Docs, news articles,
Job description Location : Basel, Geneva, Zurich Work Pattern Percentage : 80-100% Help our clients navigate the future with confidence and embrace decision making with clear data-driven choices Deloitte AI & Data helps clients unlock the power
Overview In this role you help clients modernise their data landscapes and unlock value from data and AI. You will design and implement data management solutions, shape data strategies, and lead end-to-end transformations in cross-functional teams. You’ll
Senior Software Engineer, Windows/Desktop Applications - Basel, Switzerland Mission The mission of Speechify is to make sure that reading is never a barrier to learning. Over 50 million people use Speechify’s text-to-speech products to turn whatever
Overview In this role, you will bridge traditional scientific publishing with AI-driven research to secure access to essential STM literature and AI-ready data. You’ll manage licensing, ensure data compliance, and collaborate with a cross-functional team to shape a
Overview In this role you will shape Adobe’s Brand Visibility platforms at the AI-native frontier, architecting systems that stay relevant over years and scaling AI-driven brand intelligence. You’ll cross-functionally define AI architecture, build shared tooling, and drive the org toward
Overview You will enable better infrastructure decision-making across cloud, on-prem, AI infrastructure, and shared platforms. In this role you partner with R&D, finance, and procurement to improve visibility, forecasting, and governance, translating data into decision-ready insights. You drive
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)